103 related articles for article (PubMed ID: 19530240)
21. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
Zuo BL; Yan B; Zheng GX; Xi WJ; Zhang X; Yang AG; Jia LT
Cancer Immunol Immunother; 2018 Mar; 67(3):393-401. PubMed ID: 29127433
[TBL] [Abstract][Full Text] [Related]
22. A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration.
Cabrera RM; Mao SPH; Surve CR; Condeelis JS; Segall JE
Breast Cancer Res; 2018 Apr; 20(1):24. PubMed ID: 29636067
[TBL] [Abstract][Full Text] [Related]
23. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
24. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.
Lee CY; Lin Y; Bratman SV; Feng W; Kuo AH; Scheeren FA; Engreitz JM; Varma S; West RB; Diehn M
Cancer Res; 2014 Jan; 74(1):341-52. PubMed ID: 24177178
[TBL] [Abstract][Full Text] [Related]
25. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
27. Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells.
Angelucci A; Garofalo S; Speca S; Bovadilla A; Gravina GL; Muzi P; Vicentini C; Bologna M
Endocr Relat Cancer; 2008 Mar; 15(1):91-100. PubMed ID: 18310278
[TBL] [Abstract][Full Text] [Related]
28. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
Blackburn E; Zona S; Murphy ML; Brown IR; Chan SK; Gullick WJ
Breast Cancer Res Treat; 2012 Jul; 134(1):53-9. PubMed ID: 22169894
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression.
Hardy S; Wong NN; Muller WJ; Park M; Tremblay ML
Cancer Res; 2010 Nov; 70(21):8959-67. PubMed ID: 20841483
[TBL] [Abstract][Full Text] [Related]
30. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
32. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer.
Tan JX; Wang XY; Li HY; Su XL; Wang L; Ran L; Zheng K; Ren GS
Int J Cancer; 2011 Mar; 128(6):1303-15. PubMed ID: 20473947
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
34. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling.
Teng Y; Pi W; Wang Y; Cowell JK
Oncogene; 2016 Sep; 35(35):4633-40. PubMed ID: 26804171
[TBL] [Abstract][Full Text] [Related]
35. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
[TBL] [Abstract][Full Text] [Related]
36. Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.
Zhang S; Mukherjee S; Fan X; Salameh A; Mujoo K; Huang Z; Li L; To'a Salazar G; Zhang N; An Z
Oncotarget; 2016 Oct; 7(40):65758-65769. PubMed ID: 27582551
[TBL] [Abstract][Full Text] [Related]
37. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.
Schmitt LC; Rau A; Seifert O; Honer J; Hutt M; Schmid S; Zantow J; Hust M; Dübel S; Olayioye MA; Kontermann RE
MAbs; 2017 Jul; 9(5):831-843. PubMed ID: 28421882
[TBL] [Abstract][Full Text] [Related]
39. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer.
Park J; Sarode VR; Euhus D; Kittler R; Scherer PE
Proc Natl Acad Sci U S A; 2012 Dec; 109(51):21058-63. PubMed ID: 23213231
[TBL] [Abstract][Full Text] [Related]
40. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells.
Turner T; Chen P; Goodly LJ; Wells A
Clin Exp Metastasis; 1996 Sep; 14(4):409-18. PubMed ID: 8878415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]